M. Ychou

M. Ychou, C. V. D. van de Velde, P. Kienle, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data.

M. Ychou, C. V. D. van de Velde, P. Kienle, 2013, European journal of cancer.

Gastroesophageal adenocarcinomas -N eoadjuvant and adjuvant treatments in 2011: Ar eview

M. Ychou, E. Samalin, 2011 .

Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts?

M. Ychou, E. Samalin, 2007, Current opinion in oncology.

Surgery for Esophageal Cancer after Concomitant Radiochemotherapy: Oncologic and Functional Results

M. Ychou, P. Rouanet, C. Lemanski, 2004, World Journal of Surgery.

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

M. Ychou, T. Frebourg, F. Blanchard, 2009, British Journal of Cancer.

Bone metastases in gastrointestinal cancer

M. Ychou, E. Assenat, T. Mazard, 2014, Clinical & Experimental Metastasis.

Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization

M. Ychou, C. Bascoul-Mollevi, E. Assenat, 2009, BMC Molecular Biology.

No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families

M. Ychou, M. Picot, P. Taourel, 2021, Genes.

Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.

M. Ychou, J. Douillard, F. Goldwasser, 2012, Clinical colorectal cancer.

Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study).

B. Chauffert, T. Conroy, M. Ychou, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial

M. Ychou, B. Nordlinger, M. Rivoire, 2004 .

Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial.

M. Ychou, B. Nordlinger, M. Rivoire, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Future prospects for palliative care of mCRC

M. Ychou, 2008 .

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

A. Lièvre, M. Ychou, P. Rougier, 2009, BMC Cancer.

Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study.

T. Conroy, M. Ychou, M. Ducreux, 2005, European journal of cancer.

Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen

F. Pinguet, M. Ychou, J. Duffour, 2003, Cancer Chemotherapy and Pharmacology.

Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer.

P. Couzigou, M. Ychou, M. Ducreux, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

M. Ychou, J. Duffour, M. Ducreux, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

M. Ychou, G. Deplanque, Y. Bécouarn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer

T. Conroy, M. Ychou, M. Ducreux, 2011, International journal of cancer.

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

T. Conroy, M. Ychou, M. Ducreux, 2009, British Journal of Cancer.

Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC)

T. Conroy, M. Ychou, M. Ducreux, 2007 .

Restorative and Nonrestorative Surgery for Low Rectal Cancer After High-Dose Radiation

M. Ychou, P. Rouanet, A. Kramar, 2002, Diseases of the colon and rectum.

Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer

M. Ychou, M. Ducreux, M. Hebbar, 2009, Journal of Cancer Research and Clinical Oncology.

Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.

R. Labianca, M. Ychou, S. Cascinu, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy.

M. Ychou, J. Duffour, S. Nougaret, 2012, Radiology.

Adjuvant Radioimmunotherapy Trial with Iodine-131–Labeled Anti–Carcinoembryonic Antigen Monoclonal Antibody F6 F(ab′)2 after Resection of Liver Metastases from Colorectal Cancer

M. Ychou, P. Rouanet, C. Bascoul-Mollevi, 2008, Clinical Cancer Research.

Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors

M. Ychou, B. Dréno, O. Bouché, 2012, Supportive Care in Cancer.

Phase III randomised trial Intraoperative radiotherapy of rectal cancer : Results of the French multi-institutional randomized study

M. Ychou, S. Mathoulin-Pélissier, P. Rouanet, 2011 .

Intra-operative radiotherapy of rectal cancer: results of the French multi-institutional randomized study.

M. Ychou, S. Mathoulin-Pélissier, P. Rouanet, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancer.

M. Ychou, P. Rouanet, E. Assenat, 2007, International journal of radiation oncology, biology, physics.

p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis

M. Ychou, F. Bibeau, J. Grenier, 2005, British Journal of Cancer.

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

T. Conroy, M. Ychou, M. Ducreux, 2011, Oncology.

Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting

M. Ychou, J. Douillard, J. Seitz, 2008, Oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.

B. Chauffert, M. Ychou, M. Ducreux, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab

J. Vauthey, M. Ychou, Haesun Choi, 2017, Gut.

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer

T. Conroy, M. Ychou, M. Ducreux, 2008, British Journal of Cancer.

Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.

M. Ychou, Y. Bécouarn, R. Guimbaud, 2011, Clinics and research in hepatology and gastroenterology.

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

D. Sargent, M. Ychou, R. Goldberg, 2013, The Lancet.

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

M. Ychou, E. Van Cutsem, A. Grothey, 2018, The oncologist.

Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.

M. Ychou, C. V. D. van de Velde, M. Kieser, 2019, European journal of cancer.

Initial endoscopic description of esophageal squamous cell carcinomas.

M. Ychou, E. Assenat, P. Pouderoux, 2006, Gastroenterologie clinique et biologique.

Cancer of the stomach.

M. Ychou, D. Pezet, P. Michel, 2006, Gastroenterologie clinique et biologique.

Imaged-guided liver stereotactic body radiotherapy using VMAT and real-time adaptive tumor gating. Concerns about technique and preliminary clinical results.

M. Ychou, P. Rouanet, O. Riou, 2017, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study.

M. Ychou, P. Rougier, J. Douillard, 2000, American journal of clinical oncology.

Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors a prospective phase II study in 24 patients

M. Ychou, P. Legmann, P. Rougier, 1993, Cancer.

Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre

M. Ychou, P. Rougier, R. Guimbaud, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802)

M. Ychou, J. Douillard, Y. Bécouarn, 2005 .

Detection of lymph node metastases in lung cancer: comparison of 131I-anti-CEA-anti-CA 19-9 immunoscintigraphy versus computed tomography.

M. Ychou, J. Pujol, P. Godard, 1994, Lung cancer.

Validation of an appropriate reference gene for normalization of RT-qPCR data from rectal cancer biopsies

Evelyne, M. Ychou, C. Bascoul-Mollevi, 2009 .

Validation of an appropriate reference gene for normalization of reverse transcription-quantitative polymerase chain reaction data from rectal cancer biopsies.

M. Ychou, C. Bascoul-Mollevi, E. Assenat, 2009, Analytical Biochemistry.

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours

M. Ychou, J. Pujol, W. Jacot, 2004, The British journal of dermatology.

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Radiation recall: a well recognized but neglected phenomenon.

N. Magné, S. Culine, R. Stupp, 2005, Cancer treatment reviews.

Modulating PKCα Activity to Target Wnt/β-Catenin Signaling in Colon Cancer

M. Ychou, P. Blache, J. Haigh, 2019, Cancers.

Potential contribution of 131I-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: pretherapeutic study with dose recovery in resected tissues.

M. Ychou, P. Rougier, F. Eschwège, 1993, European journal of cancer.

[Therapeutic management of hepatic metastases from colorectal cancers].

M. Ychou, P. Rougier, J. Delpero, 2003, Gastroenterologie clinique et biologique.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

Small cell carcinoma with concomitant adenocarcinoma arising in a Barrett’s oesophagus: report of a case with a favourable behaviour

M. Ychou, E. Assenat, F. Bibeau, 2007, Virchows Archiv.

Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF

M. Ychou, B. Robert, C. Gongora, 2013 .

Metastatic Gastrointestinal Cancer: Safety of Cisplatin Combined with Continuous 5-FU Versus Bolus 5-FU and Leucovorin (Methodology)

M. Ychou, J. Duffour, M. Ducreux, 2008 .

Survey on the management of skin toxicity associated with EGFR inhibitors amongst French Physicians

M. Ychou, B. Dréno, O. Bouché, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm

M. Ychou, B. Dréno, M. Richard, 2012, Supportive Care in Cancer.

The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastases.

M. Ychou, O. Sgarbura, T. Mazard, 2022, Surgery.

Management of colorectal peritoneal metastases: Expert opinion.

M. Ychou, M. Ducreux, M. Pocard, 2019, Journal of visceral surgery.

Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma with Combined Radiochemotherapy with 5-Fluorouracil and Cisplatin

M. Ychou, W. Jacot, C. Lemanski, 2002, Pancreas.

A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial

M. Ychou, M. Ducreux, C. Létoublon, 2013, Annals of Surgical Oncology.

A randomized phase III study comparing adjuvant 5-ﬂuorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer

C. Bokemeyer, M. Ychou, W. Hohenberger, 2009 .

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial.

M. Ychou, E. Assenat, Y. Bécouarn, 2016 .

Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (LMCRC). (METHEP)

M. Ychou, M. Ducreux, R. Guimbaud, 2008 .

Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301)

C. Bokemeyer, M. Ychou, P. Gascón, 2008 .

Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer

M. Ychou, B. Robert, P. Martineau, 2003, British Journal of Cancer.

Efficacy of 5FU + cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC)

J. Pignon, M. Ychou, M. Ducreux, 1999 .

Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II study.

T. Conroy, M. Ychou, M. Ducreux, 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).

M. Ychou, J. Duffour, M. Ducreux, 2006, Anticancer research.

Reply to E.C. Smyth et al and E. Elimova et al.

M. Ychou, P. Rougier, R. Guimbaud, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results

M. Ychou, G. Deplanque, Y. Bécouarn, 2017 .

EC3 COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING

T. Conroy, M. Ychou, M. Ducreux, 2007 .

Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study.

M. Ychou, L. Mineur, F. Viret, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (P) versus surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC 94012-FFCD 9703 trial.

J. Pignon, T. Conroy, M. Ychou, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial

T. Conroy, M. Ychou, M. Ducreux, 2007 .

[Should cases of hepatocellular carcinoma be discussed by non-specialized multidisciplinary team meetings?].

M. Ychou, D. Franco, J. Raoul, 2014, Bulletin du cancer.

Reproductive Decision-Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options

M. Ychou, J. Duffour, E. Crapez, 2016, Journal of Genetic Counseling.

Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort

M. Ychou, P. Rougier, T. Mazard, 2014, Gastric Cancer.

PD-0034POPULATION PHARMACOKINETICS ANALYSIS OF REGORAFENIB AND ITS ACTIVE METABOLITES FROM THE PHASE III CORRECT STUDY OF METASTATIC COLORECTAL CANCER

M. Ychou, J. Tabernero, A. Grothey, 2013 .

[Gemcitabine and ionizing radiations: radiosensitization or radio-chemotherapy combination].

S. Culine, M. Ychou, W. Jacot, 2002, Bulletin du cancer.

Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma

C. Auffray, Y. Pommier, M. Ychou, 2002, FEBS letters.

Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis

T. Conroy, M. Ychou, M. Ducreux, 2005 .

The landscape of cancer-associated fibroblasts in colorectal cancer liver metastases

J. Colinge, M. Ychou, P. Colombo, 2022, Theranostics.

Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib

M. Ychou, R. Goldberg, H. Lenz, 2013 .

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

J. Pignon, T. Conroy, M. Ychou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model

M. Ychou, B. Robert, A. Pèlegrin, 1999, British Journal of Cancer.

Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.

M. Ychou, B. Robert, A. Pèlegrin, 1996, Cancer research.

Time course of regorafenib-associated adverse events in the phase III CORRECT study.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)

B. Chauffert, M. Ychou, P. Rougier, 2010, Gut.

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.

M. Ychou, E. Assenat, J. Biagi, 2022, JAMA oncology.

A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.

F. Pinguet, M. Ychou, J. Duffour, 2007, Oncology reports.

Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study

M. Ychou, P. Colombo, E. Assenat, 2022, Cancers.

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

P. Laurent-Puig, M. Ychou, G. Deplanque, 2019, Annals of Oncology.

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

T. Conroy, M. Ychou, C. Bascoul-Mollevi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

S. Culine, T. Conroy, M. Ychou, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

M. Ychou, B. Dréno, P. Gourraud, 2012, The oncologist.

Association of neutrophil extracellular traps with the production of circulating DNA in patients with colorectal cancer

M. Ychou, T. Mazard, J. Abraham, 2022, iScience.

A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer

M. Ychou, A. Stein, F. Loupakis, 2015, Targeted Oncology.

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Lecomte, Sophie Gourgou, T. Conroy, 2018, The New England journal of medicine.

Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.

A. Lièvre, M. Ychou, O. Bouché, 2016, Clinical colorectal cancer.

Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts

M. Ychou, B. Robert, F. Molina, 2010, Nucleic acids research.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

D. Sargent, M. Teufel, M. Ychou, 2015, The Lancet. Oncology.

High Fragmentation Characterizes Tumour-Derived Circulating DNA

M. Ychou, B. Robert, F. Molina, 2011, PloS one.

Quantification of HER Expression and Dimerization in Patients’ Tumor Samples Using Time-Resolved Förster Resonance Energy Transfer

M. Ychou, C. Bascoul-Mollevi, J. Ramos, 2012, PloS one.

Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy.

S. Culine, M. Ychou, G. Romieu, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.

C. Bokemeyer, M. Ychou, A. Santoro, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Time course of regorafenib-associated adverse events in the phase III CORRECT study

M. Ychou, R. Goldberg, H. Lenz, 2013 .

Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival

J. Pignon, M. Ychou, M. Ducreux, 2011, Radiation oncology.

A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer

M. Ychou, P. Rouanet, C. Bascoul-Mollevi, 2011, The Pharmacogenomics Journal.

Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas.

M. Ychou, P. Martineau, M. Del Rio, 2008, European journal of cancer.

Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum.

J. Pignon, M. Ychou, M. Ducreux, 1994, European journal of cancer.

Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)

Daniel J. Sargent, Olivier Bouché, Alberto Sobrero, 2012 .

Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR.

A. Vincent-Salomon, M. Ychou, M. Stern, 2018, Clinical chemistry.

Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site.

S. Culine, F. Pinguet, M. Ychou, 2003, Anticancer research.

5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site.

S. Culine, M. Ychou, G. Romieu, 2001, Anticancer research.

Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.

M. Ychou, N. Vié, P. Martineau, 2017, European journal of cancer.

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

T. Conroy, M. Ychou, M. Ducreux, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.

M. Ychou, M. Reni, D. Richel, 2014, Cancer treatment reviews.

SOX9 is an atypical intestinal tumor suppressor controlling the oncogenic Wnt/ß-catenin signaling

Philippe Blache, M. Ychou, P. Blache, 2016, Oncotarget.

Docetaxel and Radiotherapy and Pancreatic Cancer

M. Ychou, P. Viens, G. Gravis, 2003, Pancreas.

Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer

A. Sézeur, M. Ychou, J. Pascussi, 2017, Clinical Cancer Research.

Targeting the Wnt pathway and cancer stem cells with anti-progastrin humanized antibodies : a major breakthrough for KRAS mutated colorectal cancer treatment

A. Sézeur, M. Ychou, J. Pascussi, 2017 .

Sorafenib Overcomes Irinotecan Resistance in Colorectal Cancer by Inhibiting the ABCG2 Drug-Efflux Pump

M. Ychou, A. Causse, B. Robert, 2013, Molecular Cancer Therapeutics.

Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial

M. Ychou, E. Assenat, C. Mollevi, 2021, ESMO open.

Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.

M. Ychou, P. Rouanet, F. Viret, 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.

M. Ychou, E. Assenat, F. Bibeau, 2011, The oncologist.

Two‐stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second‐stage completion and longer survival☆

M. Ychou, P. Rouanet, O. Sgarbura, 2019, Surgery.

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial

M. Ychou, E. Assenat, R. Guimbaud, 2022, British Journal of Cancer.

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer

M. Ychou, T. Mazard, F. Ghiringhelli, 2021, BMC cancer.

Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in veterans.

P. Polak, T. Fojo, S. Bates, 2021, Seminars in oncology.

Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)

M. Ychou, E. Assenat, C. Lombard-Bohas, 2021, International journal of cancer.

A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort

S. Truant, M. Ychou, P. Colombo, 2018, BMC Cancer.

Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)

T. Conroy, M. Ychou, O. Bouché, 2017, Oncology.

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma

M. Buyse, T. Conroy, M. Ychou, 2016, Oncotarget.

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial

M. Ychou, B. Robert, E. Crapez, 2015, Oncotarget.

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012

R. Labianca, M. Büchler, J. Berlin, 2013 .

The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer

T. Conroy, M. Ychou, M. Ducreux, 2013, Current Oncology Reports.

Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma.

M. Ychou, P. Rougier, F. Bonnetain, 2010, European journal of cancer.

Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma

M. Ychou, E. Assenat, O. Riou, 2021, Cancers.

A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth

M. Ychou, P. Blache, C. Prévostel, 2019, Molecular Cancer Therapeutics.

Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment

M. Ychou, E. Assenat, C. Borg, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray

M. Ychou, F. Penault-Llorca, P. Rochaix, 2006, Virchows Archiv.

Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer

F. Pinguet, M. Ychou, J. Duffour, 2007, Cancer Chemotherapy and Pharmacology.

High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer

M. Ychou, C. Borel, F. Caroli-Bosc, 2002, Cancer Chemotherapy and Pharmacology.

Specific Extracellular Matrix Remodeling Signature of Colon Hepatic Metastases

Caroline Mollevi, Pierre Martineau, Frédéric Bibeau, 2013, PloS one.

Hepatic metastases from carcinomas of unknown primary site.

S. Culine, M. Ychou, D. Pouessel, 2005, Gastroenterologie clinique et biologique.

Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review.

N. Girard, M. Ychou, J. Scoazec, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m)

M. Ychou, A. Grothey, F. Ciardiello, 2016 .

[Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].

S. Culine, M. Ychou, B. Robert, 2003, Bulletin du cancer.

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel.

M. Ychou, E. Van Cutsem, B. Nordlinger, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.

Agnès Laplanche, Michel Ducreux, M. Ychou, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.

M. Ychou, M. Ducreux, P. Rougier, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial).

M. Ychou, E. Assenat, Y. Bécouarn, 2013 .

Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial

J. Pignon, T. Conroy, M. Ychou, 2007 .

Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis.

J. Pignon, M. Ychou, M. Ducreux, 1994, European journal of cancer.

Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen

F. Pinguet, M. Ychou, J. Duffour, 2006, Cancer Chemotherapy and Pharmacology.

Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.

M. Ychou, E. Van Cutsem, H. Lenz, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI).

T. Conroy, P. Laurent-Puig, M. Ychou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumors.

S. Culine, F. Pinguet, M. Ychou, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer.

M. Ychou, P. Perney, P. Fabbro-Péray, 1998, American journal of clinical oncology.

[Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?]

M. Ychou, T. Mazard, A. Adenis, 2020 .

Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study.

M. Ychou, J. Duffour, O. Dereure, 2010, European journal of cancer.

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

T. Conroy, M. Ychou, F. Penault-Llorca, 2021, ESMO Open.

A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.

J. Pignon, M. Ychou, M. Ducreux, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801).

M. Ychou, B. Nordlinger, M. Ducreux, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer.

M. Ychou, C. Astre, P. Rouanet, 1996, European journal of cancer.

Determinants of distinct trajectories of fatigue in patients undergoing chemotherapy for a metastatic colorectal cancer: 6-month follow-up using Growth Mixture Modeling.

M. Ychou, F. Cousson-Gélie, V. Philipps, 2021, Journal of pain and symptom management.

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.

D. Aust, J. Ajani, M. Ychou, 2012, European journal of cancer.

Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†.

M. Buyse, M. Ychou, P. Rougier, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer

M. Ychou, P. Rouanet, C. Bascoul-Mollevi, 2011, International journal of cancer.

Gemcitabine and docetaxel as front‐line chemotherapy in patients with carcinoma of an unknown primary site

S. Culine, F. Pinguet, M. Ychou, 2004, Cancer.

Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial.

N. Girard, M. Ychou, M. Ducreux, 2006, International journal of radiation oncology, biology, physics.

Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from digestive tract cancer—New management with oxaliplatin plus irinotecan: A feasibility study in 37 patients

M. Ychou, P. Rouanet, A. Gauthey, 2008 .

Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody.

André Pèlegrin, Sophie Gourgou, Pierre Martineau, 2003, International journal of radiation oncology, biology, physics.

Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study

M. Ychou, E. Assenat, T. Mazard, 2023, Journal of clinical medicine.

Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer

M. Ychou, S. Kopetz, M. Overman, 2017, Clinical Cancer Research.

Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

D. Kerr, R. Lothe, V. Moreno, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.

A. Carrato, V. Georgoulias, M. Ychou, 2007, European journal of cancer.

Phase‐I/II radio‐immunotherapy study with iodine‐131‐labeled anti‐CEA monoclonal antibody F6 F(ab′)2 in patients with non‐resectable liver metastases from colorectal cancer

J. Rossi, M. Ychou, B. Robert, 1998, International journal of cancer.

LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

M. Ychou, E. Assenat, O. Bouché, 2021, Annals of Oncology.

Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial

M. Ychou, E. Assenat, Y. Bécouarn, 2019, British Journal of Cancer.

A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer

M. Ychou, E. Crapez, T. Mazard, 2023, Scientific Reports.

Neoadjuvant therapy for gastroesophageal adenocarcinoma.

M. Ychou, E. Samalin, 2016, World journal of clinical oncology.

Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer

M. Ychou, P. Rouanet, M. Ozsahin, 2005, BMC Cancer.

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

R. Labianca, J. Meyerhardt, M. Shah, 2020, European Journal of Cancer.

A phase III randomised trial of LV 5 FU 2 1 irinotecan versus LV 5 FU 2 alone in adjuvant high-risk colon cancer ( FNCLCC Accord 02 / FFCD 9802 )

T. Conroy, M. Ychou, M. Ducreux, 2009 .

Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer

M. Ychou, E. Assenat, D. Botsen, 2021, JAMA network open.

Differences in coagulability of three glutaraldehyde solutions in the glutaraldehyde test on bovine whole blood.

M. Ychou, M. Chadli, L. Mahin, 2010, Zentralblatt fur Veterinarmedizin. Reihe A.

Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.

T. Conroy, M. Ychou, J. Douillard, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM

F. Bertucci, M. Ychou, J. Pascussi, 2021, Cancers.

Clinical Impact of Intensified 5-Fluorouracil-Based Chemotherapy Using a Prospective Pharmacokinetically-Guided Dosing Approach: Comparative Study in Elderly and Non-Elderly Patients with Metastatic Colorectal Cancer

F. Pinguet, M. Ychou, J. Duffour, 2010 .

Antibody targeting of claudin-1 as a potential colorectal cancer therapy

M. Ychou, V. Denis, P. Martineau, 2017, Journal of experimental & clinical cancer research : CR.

Association of FcγRIIa and FcγRIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan

M. Ychou, E. Crapez, T. Frebourg, 2008 .

Gene expression signature for the prediction of FOLFIRI response in advanced colorectal cancer patients

Caroline, M. Ychou, V. Copois, 2010 .

Sequential treatment with Nab-paclitaxel plus Gemcitabine and Folfirinox in metastatic pancreatic adenocarcinoma: GABRINOX phase II results.

M. Ychou, E. Assenat, T. Mazard, 2018 .

Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study

M. Ychou, J. Daurès, E. Assenat, 2021, Cancers.

Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.

N. Girard, B. Chauffert, M. Ychou, 2010, International journal of radiation oncology, biology, physics.

Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer

J. M. Joulia, F. Pinguet, M. Ychou, 1999, Cancer Chemotherapy and Pharmacology.

Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer.

J. M. Joulia, F. Pinguet, M. Ychou, 1999, Anticancer Research.

Bone metastases in gastrointestinal cancer

M. Ychou, E. Assenat, T. Mazard, 2014, Clinical & Experimental Metastasis.

Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer.

M. Ychou, J. Duffour, A. Kramar, 2002, Anticancer research.

Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma

M. Ychou, T. Mazard, A. Adenis, 2021, AntiCancer Research.

[Recommendations for clinical practice: management of stomach adenocarcinoma].

M. Ychou, O. Bouché, Y. Merrouche, 2006, Bulletin du Cancer.

[Stomach adenocarcinomas: comparison between CA 19-9 and carcinoembryonic antigen for the diagnosis of recurrences after surgical treatment].

J. Pignon, M. Ychou, J. Bidart, 1992, Gastroenterologie clinique et biologique.

Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2).

J. M. Joulia, F. Pinguet, M. Ychou, 1997, Anticancer research.

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)

V. Torri, M. Ychou, E. Van Cutsem, 2016, ESMO Open.

[Irinotecan in combination for colon cancer].

M. Ychou, M. Ducreux, D. Khayat, 1998, Bulletin du cancer.

Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial

W. Cacheux, M. Ychou, M. Stern, 2016 .

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma

V. Gebski, J. Pignon, P. Schlag, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RIP140 increases APC expression and controls intestinal homeostasis and tumorigenesis.

M. Ychou, P. Roepman, C. Bascoul-Mollevi, 2014, The Journal of clinical investigation.

Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study

M. Ychou, O. Sgarbura, T. Mazard, 2016, Pleura and peritoneum.

Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site

S. Culine, F. Pinguet, M. Ychou, 2002, Cancer.

Toxidermie au raltitrexed : 2 cas

M. Ychou, B. Guillot, I. Hellier, 2000 .

Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801).

M. Ychou, B. Nordlinger, M. Ducreux, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study evaluating the association of gemcitabine, trastuzumab, and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).

M. Ychou, E. Assenat, C. Lombard-Bohas, 2015 .

Modulating PKCα Activity to Target Wnt/β-Catenin Signaling in Colon Cancer

M. Ychou, P. Blache, J. Haigh, 2019, Cancers.

Conservative Surgery for Low Rectal Carcinoma After High‐Dose Radiation Functional and Oncologic Results

M. Ychou, P. Rouanet, H. Pujol, 1995, Annals of surgery.

RIP 140 increases APC gene expression and controls intestinal homeostasis and tumorigenesis

M. Ychou, C. Bascoul-Mollevi, F. Hollande, 2014 .

Safety analysis of the French Intergroup R98 trial comparing 5FU-leucovorin alone or with irinotecan in resected stages II-III rectal cancers

M. Ychou, P. Rougier, J. Douillard, 2008 .

[Contribution of endorectal ultrasonography in preoperative evaluation for very low rectal cancer].

M. Ychou, C. Lemanski, F. Quénet, 2001, Gastroenterologie clinique et biologique.

Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial

M. Ychou, E. Assenat, Y. Bécouarn, 2019, British Journal of Cancer.

Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.

M. Ychou, E. Assenat, Y. Bécouarn, 2018 .

Results of a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (CORRECT) of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients with Metastatic Colorectal Cancer (MCRC) who have Progressed after Standard Therapies

M. Ychou, A. Grothey, H. Lenz, 2012 .

Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.

M. Ychou, E. Assenat, T. Mazard, 2012, World journal of gastroenterology.

Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study

M. Ychou, P. Colombo, E. Assenat, 2022, Frontiers in Oncology.

[The value of tumor markers in digestive oncology].

M. Ychou, J. Bidart, P. Rougier, 1989, Annales de Chirurgie.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

J. Reid, A. Lièvre, P. Laurent-Puig, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.

M. Ychou, M. Reni, D. Richel, 2014, Cancer treatment reviews.

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel.

M. Ychou, B. Nordlinger, T. Gruenberger, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniques.

M. Ychou, E. Assenat, O. Riou, 2017, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

6091 POSTER Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)

P. Laurent-Puig, M. Ychou, O. Bouché, 2011 .

Cost-minimization analysis of a phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting

T. Conroy, M. Ychou, M. Ducreux, 2007 .

[The reference site of the European Innovation Partnership on Active and Healthy Aging MACVIA-LR (the fight against chronic diseases for an active and healthy aging in Languedoc-Roussillon)].

P. Claret, J. Robine, B. Bardy, 2015, Presse medicale.

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

T. Conroy, M. Ychou, C. Bascoul-Mollevi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU plus irinotecan plus leucovorin (FOLFIRI) or capecitabine plus irinotecan XELIRI plus bevacizumab.

B. Chauffert, T. Conroy, M. Ychou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial.

F. Pruvot, M. Ychou, F. Bonnetain, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.

M. Ychou, P. Rouanet, F. Viret, 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.